title: Interferon-alpha therapy increases type I insulin-like growth factor receptors expression on lymphoid cells from patients with chronic myelogenous leukemia.
abstract: Aiming to verify if insulin-like growth factor type I and its receptor (IGF-IR) are implicated on pathophysiology of chronic myelogenous leukemia (CML), we studied 35 patients with CML in chronic phase at diagnosis or during interferon-alpha (IFN-A) or hydroxyurea treatments. Cytometry flow analysis and reverse transcription PCR (RT-PCR) molecular assay for IGF-IR expression on peripheral blood cells from CML patients diagnosed didn't show statistical differences from the control group. Hydroxyurea treated patients had lower expression of IGF-IR in granulocytes, lymphocytes and monocytes (P<0.01). We found statistical higher percentage of T and B lymphocytes positive for IGF-IR on IFN-A treated patients (P<0.001). Also an increase of IGF-IR mRNA expression could be detected in this group when compared with patients in hydroxyurea therapy (P<0.05). Our study suggest that IGF-IR is not directly implicated on CML installation and that the increased expression of IGF-IR on lymphoid cells of IFN-A treated patients could contribute to the immune recognition of malignant cell clone by enhancing immunocompetent cell proliferation and action.
authors.affiliation: Fundação Pró-Sangue Hemocentro de São Paulo (Cancer Research), University of São Paulo School of Medicine, Sao Paulo, Brazil.
authors.forename: M R
authors.initials: MR
authors.lastname: Oliveira
authors.forename: L
authors.initials: L
authors.lastname: Ohnuma
authors.forename: I
authors.initials: I
authors.lastname: Bendit
authors.forename: P
authors.initials: P
authors.lastname: Dorlhiac-Lacer
authors.forename: D
authors.initials: D
authors.lastname: Giannella-Neto
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D002648:Child; D005260:Female; D005434:Flow Cytometry; D006098:Granulocytes / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007334:Insulin-Like Growth Factor I / Q000378:metabolism / Q000502:physiology; D016898:Interferon-alpha / Q000627:therapeutic use*; D015466:Leukemia, Myeloid, Chronic-Phase / Q000097:blood* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D017526:Receptor, IGF Type 1 / Q000096:biosynthesis*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha; D007334:Insulin-Like Growth Factor I; D017526:Receptor, IGF Type 1; D006918:Hydroxyurea